Trial Profile
A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Novartis
- 12 May 2016 Results (pooled analysis of this and other nine studies, n = 3993) assessing safety of secukinumab published in the Journal of the American Academy of Dermatology.
- 05 Mar 2013 Results for the effect of secukinumab on high-sensitivity C-reactive protein presented at the 71st Annual Meeting of the American Academy of Dermatology.
- 05 Mar 2013 Results with focus on lipid profile and tolerability presented at the 71st Annual Meeting of the American Academy of Dermatology.